An update on the medical treatment of Crohn's disease

Panminerva Medica

Volumn 45, Issue 1, 2003, Pages 15-22

  Valentini, G ^a   Guidi, L ^a   Costanzo, M ^a   Ciarniello, M ^a   De Vitis, I ^a   Capristo, E ^a   Fedeli, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Crohn disease, diagnosis; Crohn disease, diet therapy; Crohn disease, drug therapy; Enteral nutrition

Indexed keywords

AMINOSALICYLIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZATHIOPRINE; AZITHROMYCIN; BALSALAZIDE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; FLUTICASONE PROPIONATE; FUSIDIC ACID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; OLSALAZINE; ORNIDAZOLE; PREDNISONE; SALAZOSULFAPYRIDINE; TIXICOL PIVALATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; AMINOSALICYLIC ACID DERIVATIVE; ANTIINFECTIVE AGENT; BIOLOGICAL PRODUCT; IMMUNOLOGICAL ADJUVANT;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ALLERGIC REACTION; ANOREXIA; BONE DEMINERALIZATION; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CHILDHOOD DISEASE; CHRONIC INFLAMMATION; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CROHN DISEASE; DIARRHEA; DISEASE COURSE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; ENTERIC FEEDING; ENTERITIS; FIBROSING ALVEOLITIS; FLUSHING; GINGIVA HYPERPLASIA; GROWTH DISORDER; HEADACHE; HEPATITIS; HUMAN; HYPERTENSION; HYPERTRICHOSIS; IMMUNOPATHOLOGY; IMMUNOTOXICITY; INSULIN RESISTANCE; LEUKOPENIA; LIPID METABOLISM; LIPID STORAGE; LIVER TOXICITY; LYMPHATIC SYSTEM TUMOR; LYMPHOMA; MALABSORPTION; MALE INFERTILITY; MALNUTRITION; NAUSEA; NEPHROTOXICITY; NUTRITIONAL STATUS; OPPORTUNISTIC INFECTION; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; REVIEW; SIDE EFFECT; TASTE DISORDER; TREATMENT INDICATION; ULCERATIVE COLITIS; VOMITING; WEIGHT REDUCTION;

ADJUVANTS, IMMUNOLOGIC; ADRENAL CORTEX HORMONES; AMINOSALICYLIC ACIDS; ANTI-BACTERIAL AGENTS; BIOLOGICAL PRODUCTS; CROHN DISEASE; ENTERAL NUTRITION; HUMANS;

EID: 0037810610     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991;325:928-37.
2. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
3. Hampe J, Cuthbert A, Croucher PJP, Mirza MM, Mascheretti S, Fisher S et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357:1925-8.
4. Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn's disease. Gut 1993;34:939-43.
5. Svartz N. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. Am J Gastroenterol 1988;83:497-503.
6. Greenfield SM, Punchard NA, Teare JP, Thompson RP. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 1993;7:369-83.
7. Sharon P, Stenson WF. Metabolism of arachidonic acid in acetic acid colitis in rats: similarity to human inflammatory bowel disease. Gastroenterology 1985;88:55-62.
8. Stevens C, Lipman M, Fabry S, Moscovitch-Lopatin M, Almawi W, Keresztes S et al. 5-Aminosalicylic acid abrogates blood mononuclear cells. J Pharmacol Exp Ther 1995;272:399-406.
9. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD et al. Mesalamine capsules for the treatment of active Crohn's disease: results of 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993;104:1293-301.
10. Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465-73.
11. Goulding NJ, Euzger HS, Butt SK, Perretti M. Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation. Inflamm Res 1998;47:S158-65.
12. Angeli A, Masera RG, Sartori ML, Fortunati N, Racca S, Dovio A et al. Modulation by cytokines of glucocorticoid action. Ann N Y Acad Sci 1999;876:210-20.
13. Regueiro MD, Peppercorn MA. New therapeutic agents. In: Friedmann G, Jacobson ED, Mc Callum RN, editors: Gastrointestinal pharmacology and therapeutics. Philadelphia: Lippincott-Raven; 1997.p.349-65.
14. Colombel JF, Cortot A, van Kruiningen HJ. Antibiotics in Crohn's disease. Gut 2001;48:647.
15. Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn's ileitis? J Clin Gastroenterol 1993;17:235-7.
16. Wolf JL. Ciprofloxacin may be useful in Crohn's disease. Gastroenterology 1990;98:A212.
17. Colombel JF, Lemann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999;94:674-8.
18. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine and methotrexate. Am J Gastroenterol 1996;91:423-33.
19. Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 1990;30:358-63.
20. O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 1991;101:39-46.
21. Korelitz BI, Present DH. Favourable effect of 6-mercaptopurine on fistulae of Crohn's disease. J Clin Gastroenterol 1985;30:58-64.
22. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C et al. Long term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347:215-9.
23. Weinshilboun RM, Sladek SL. 6-mercaptopurine pharmacogenetics: monogenic inheritance of erytrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
24. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30.
25. Seitz M. Molecular and cellular effects of methotrexate. Curr Opin Rheumatol 1999;11:226-32.
26. Farrel RJ, Shan SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P et al. Clinical experience with Infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000;95:3490-7.
27. Present DH, Rutgeerts P, Targan S, Hanauer S, Mayer L, van Hogezand RA et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
28. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000;95:3469-77.
29. Rutgeer P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH et al. Efficacy and safety of retreatment with anti-tumour necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
30. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000;119:1781-3.
31. Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999;117:58-64.
32. Gaggiotti G. Manuale di nutrizione enterale. Torino: Edizioni Minerva Medica; 1990.p.13.
33. Ruemmele FM, Roy C, Levi E, Seidman E. Nutrition as primary therapy in pediatric Crohn's disease: fact or fantasy? J Pediatr 2000; 136:285-91.
34. Henschkel RB, Monache CC, Megarian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 2000;31:8-15.
35. Gonzalez-Huix F, de Leon R, Fernandez-Banares F, Esteve M, Cabre E, Acero D et al. Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. Gut 1993;34:778-82.
36. Fernandez-Banares F, Cabre E, Esteve M, Gassull MA. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomised controlled trials. J PEN 1995;19:356-64.
37. Winitz M, Seedman DA, Gruff J. Studies in metabolic nutrition employing chemically defined diet on human fecal flora. Am J Clin Nutr 1970; 23:525-45.
38. Bounous G, Devroeda GJ. Effects of an elemental diet on human fecal flora. Gastroenterology 1974;66:210-4.
39. Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993;341:1437-9.
40. Teahon K, Smethurst P, Macpherson AJ, Levi AJ, Menzies IS, Bjarnason I. Intestinal permeability in Crohn's disease and its relation to disease and relapse following treatment with elemetal diet. Eur J Gastroenterol Hepatol 1993;5:79-84.
41. Teahon K, Smethurst P, Pearson M, Levi AJ, Bjarnason I. The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease. Gastroenterology 1991;101:84-9.
42. Fell JM, Paintin M, Arnaud-Battandier F, Beattie RM, Hollis A, Kitching P et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000;14:281-9.
43. Hanauer SB. Review articles: drug therapy, inflammatory bowel disease. N Engl J Med 1996;334:841-8.
44. Hanauer SB, Sandborn W. The Practice Parameters Committeee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2001;96:635-43.
45. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000;118(2 Suppl 1): 68-82.